Intevac Announces Fourth Quarter and Full Year 2018 Financial Results
Wed, January 30 2019
“We were very pleased to finish 2018 on a high note, with year-end
backlog of
($ Millions, except per share amounts) |
Q4 2018 |
Q4 2017 | |||||||||||||||||||
GAAP Results |
Non-GAAP |
GAAP Results |
Non-GAAP |
||||||||||||||||||
Net Revenues | $ | 31.6 | $ | 31.6 | $ | 24.8 | $ | 24.8 | |||||||||||||
Operating Income | $ | 1.9 | $ | 1.8 | $ | 0.2 | $ | 0.1 | |||||||||||||
Net Income (Loss) | $ | 10.0 | $ | 1.9 | $ | — | $ | (0.1 | ) | ||||||||||||
Net Income (Loss) per Diluted Share | $ | 0.44 | $ | 0.08 | $ | — | $ | — | |||||||||||||
|
Year Ended | Year Ended | |||||||||||||||||||
|
|
||||||||||||||||||||
GAAP Results |
Non-GAAP |
GAAP Results |
Non-GAAP |
||||||||||||||||||
Net Revenues | $ | 95.1 | $ | 95.1 | $ | 112.8 | $ | 112.8 | |||||||||||||
Operating Income (Loss) | $ | (4.2 | ) | $ | (4.3 | ) | $ | 4.8 | $ | 4.6 | |||||||||||
Net Income (Loss) | $ | 3.6 | $ | (4.4 | ) | $ | 4.1 | $ | 3.9 | ||||||||||||
Net Income (Loss) per Diluted Share | $ | 0.16 | $ | (0.19 | ) | $ | 0.18 | $ | 0.17 | ||||||||||||
Intevac’s non-GAAP adjusted results exclude where applicable: (1) changes in fair value of contingent consideration liabilities associated with business combinations; and (2) restructuring charges and (3) the reversal of a deferred tax asset valuation allowance. A reconciliation of the GAAP and non-GAAP adjusted results is provided in the financial table included in this release. See also “Use of Non-GAAP Financial Measures” section.
Fourth Quarter Fiscal 2018 Summary
Net income for the quarter was
Revenues were
TFE gross margin was 30.6% compared to 45.0% in the fourth quarter of 2017 and 40.2% in the third quarter of 2018. The decline from the fourth quarter of 2017 and the third quarter of 2018 reflected the lower margin on the three ENERGi solar ion implant systems.
Photonics gross margin was 42.1% compared to 26.0% in the fourth quarter of 2017 and 35.5% in the third quarter of 2018. The improvement from the fourth quarter of 2017 and the third quarter of 2018 was primarily due to higher revenue levels and favorable product mix. Consolidated gross margin was 33.5%, compared to 39.8% in the fourth quarter of 2017 and 38.5% in the third quarter of 2018.
R&D and SG&A expenses were
Order backlog totaled
The Company ended the year with
The Company repurchased 120,000 shares of common stock for a total of
Fiscal Year 2018 Summary
Net income was
Revenues were
TFE gross margin was 36.5%, compared to 42.7% in 2017. The decline from 2017 reflected the lower margin on the three ENERGi solar ion implant systems and lower factory absorption. Photonics gross margin was 28.6% compared to 35.2% in 2017, reflecting a higher mix of lower-margin research and development contracts versus product sales. Consolidated gross margin was 34.4% compared to 40.5% in 2017.
Total R&D and SG&A expenses were
Use of Non-GAAP Financial Measures
Management uses non-GAAP results to evaluate the company’s operating and
financial performance in light of business objectives and for planning
purposes. These measures are not in accordance with GAAP and may differ
from non-GAAP methods of accounting and reporting used by other
companies.
Conference Call Information
The Company will discuss its financial results and outlook in a
conference call today at
About
In our Thin-film Equipment business, we are a leader in the design and development of high-productivity, thin-film processing systems. Our production-proven platforms are designed for high-volume manufacturing of substrates with precise thin film properties, such as the hard drive media, display cover panel, and solar photovoltaic markets we serve currently.
In our Photonics business, we are a recognized leading developer of
advanced high-sensitivity digital sensors, cameras and systems that
primarily serve the defense industry. We are the provider of integrated
digital imaging systems for most
For more information call 408-986-9888, or visit the Company's website at www.intevac.com.
200 Lean®, INTEVAC MATRIX®,
INTEVAC VERTEX®, ENERGi®, and oDLC®
are registered trademarks of
Safe Harbor Statement
This press release includes statements that constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 (the “Reform Act”).
|
|||||||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||||||||
(Unaudited, in thousands, except percentages and per share amounts) |
|||||||||||||||||||||
Three months ended | Year ended | ||||||||||||||||||||
|
|
|
|
||||||||||||||||||
Net revenues | |||||||||||||||||||||
TFE | $ | 23,604 | $ | 17,916 | $ | 69,348 | $ | 79,004 | |||||||||||||
Photonics | 7,972 | 6,853 | 25,766 | 33,843 | |||||||||||||||||
Total net revenues | 31,576 | 24,769 | 95,114 | 112,847 | |||||||||||||||||
Gross profit | 10,572 | 9,847 | 32,694 | 45,663 | |||||||||||||||||
Gross margin | |||||||||||||||||||||
TFE | 30.6 | % | 45.0 | % | 36.5 | % | 42.7 | % | |||||||||||||
Photonics | 42.1 | % | 26.0 | % | 28.6 | % | 35.2 | % | |||||||||||||
Consolidated | 33.5 | % | 39.8 | % | 34.4 | % | 40.5 | % | |||||||||||||
Operating expenses | |||||||||||||||||||||
Research and development | 3,973 | 4,089 | 16,862 | 17,724 | |||||||||||||||||
Selling, general and administrative | 4,814 | 5,650 | 20,188 | 23,314 | |||||||||||||||||
Acquisition-related1 | (147 | ) | (42 | ) | (139 | ) | (223 | ) | |||||||||||||
Total operating expenses | 8,640 | 9,697 | 36,911 | 40,815 | |||||||||||||||||
Total operating income (loss) | 1,932 | 150 | (4,217 | ) | 4,848 | ||||||||||||||||
Operating income (loss) | |||||||||||||||||||||
TFE | 861 | 1,295 | (1,335 | ) | 6,116 | ||||||||||||||||
Photonics | 1,406 | 254 | 440 | 3,900 | |||||||||||||||||
Corporate | (335 | ) | (1,399 | ) | (3,322 | ) | (5,168 | ) | |||||||||||||
Total operating income (loss) | 1,932 | 150 | (4,217 | ) | 4,848 | ||||||||||||||||
Interest income and other income (expense), net | 158 | 107 | 622 | 373 | |||||||||||||||||
Income (loss) before income taxes | 2,090 | 257 | (3,595 | ) | 5,221 | ||||||||||||||||
Benefit from (provision for) income taxes | 7,893 | (298 | ) | 7,176 | (1,103 | ) | |||||||||||||||
Net income (loss) | $ | 9,983 | $ | (41 | ) | $ | 3,581 | $ | 4,118 | ||||||||||||
Net income (loss) per share | |||||||||||||||||||||
Basic | $ | 0.44 | $ | — | $ | 0.16 | $ | 0.19 | |||||||||||||
Diluted | $ | 0.44 | $ | — | $ | 0.16 | $ | 0.18 | |||||||||||||
Weighted average common shares outstanding | |||||||||||||||||||||
Basic | 22,790 | 21,794 | 22,519 | 21,555 | |||||||||||||||||
Diluted | 22,948 | 21,794 | 22,904 | 22,920 | |||||||||||||||||
1Amounts for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010. |
|
|||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
(In thousands, except par value) |
|||||||||||
|
|
||||||||||
(Unaudited) | (see Note) | ||||||||||
ASSETS | |||||||||||
Current assets | |||||||||||
Cash, cash equivalents and short-term investments | $ | 34,791 | $ | 35,639 | |||||||
Accounts receivable, net | 27,717 | 20,474 | |||||||||
Inventories | 30,597 | 33,792 | |||||||||
Prepaid expenses and other current assets | 2,528 | 2,524 | |||||||||
Total current assets | 95,633 | 92,429 | |||||||||
Long-term investments | 4,372 | 6,849 | |||||||||
Restricted cash | 1,169 | 1,000 | |||||||||
Property, plant and equipment, net | 11,198 | 12,478 | |||||||||
Intangible assets, net | 889 | 1,503 | |||||||||
Deferred income tax and other long-term assets | 8,809 | 764 | |||||||||
Total assets | $ | 122,070 | $ | 115,023 | |||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities | |||||||||||
Accounts payable | $ | 6,053 | $ | 3,949 | |||||||
Accrued payroll and related liabilities | 4,689 | 6,818 | |||||||||
Other accrued liabilities | 4,952 | 7,688 | |||||||||
Customer advances | 14,314 | 11,026 | |||||||||
Total current liabilities | 30,008 | 29,481 | |||||||||
Other long-term liabilities | 2,438 | 2,879 | |||||||||
Stockholders’ equity | |||||||||||
Common stock ( |
23 | 22 | |||||||||
Additional paid-in capital | 183,204 | 177,521 | |||||||||
|
(29,047 | ) | (28,489 | ) | |||||||
Accumulated other comprehensive income | 378 | 490 | |||||||||
Accumulated deficit | (64,934 | ) | (66,881 | ) | |||||||
Total stockholders’ equity | 89,624 | 82,663 | |||||||||
Total liabilities and stockholders’ equity | $ | 122,070 | $ | 115,023 | |||||||
Note: Amounts as of |
|
|||||||||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP RESULTS | |||||||||||||||||||||
(Unaudited, in thousands, except per share amounts) |
|||||||||||||||||||||
Three months ended |
|
Year ended |
|||||||||||||||||||
|
|
|
|
||||||||||||||||||
2018 | 2017 | 2018 | 2017 | ||||||||||||||||||
Non-GAAP Income (Loss) from Operations | |||||||||||||||||||||
Reported operating income (loss) (GAAP basis) | $ | 1,932 | $ | 150 | $ | (4,217 | ) | $ | 4,848 | ||||||||||||
Change in fair value of contingent consideration obligations1 | (147 | ) | (42 | ) | (139 | ) | (223 | ) | |||||||||||||
Restructuring charges2 | — |
— |
95 | — | |||||||||||||||||
Non-GAAP Operating Income (Loss) | $ | 1,785 | $ | 108 | $ | (4,261 | ) | $ | 4,625 | ||||||||||||
Non-GAAP Net Income (Loss) | |||||||||||||||||||||
Reported net income (loss) (GAAP basis) | $ | 9,983 | $ | (41 | ) | $ | 3,581 | $ | 4,118 | ||||||||||||
Change in fair value of contingent consideration obligations1 | (147 | ) | (42 | ) | (139 | ) | (223 | ) | |||||||||||||
Restructuring charges2 | — | — | 95 | — | |||||||||||||||||
Reversal of a deferred tax asset valuation allowance3 | (7,909 | ) | — | (7,909 | ) | — | |||||||||||||||
Income tax effect of non-GAAP adjustments4 | — | — | — | — | |||||||||||||||||
Non-GAAP Net Income (Loss) | $ | 1,927 | $ | (83 | ) | $ | (4,372 | ) | $ | 3,895 | |||||||||||
Non-GAAP Net Income (Loss) Per Diluted Share | |||||||||||||||||||||
Reported net income (loss) per diluted share (GAAP basis) | $ | 0.44 | $ | — | $ | 0.16 | $ | 0.18 | |||||||||||||
Change in fair value of contingent consideration obligations1 | $ | (0.01 | ) | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | ||||||||||
Restructuring charges2 | $ | — | $ | — | $ | — | $ | — | |||||||||||||
Reversal of a deferred tax asset valuation allowance3 | $ | (0.34 | ) | $ | — | $ | (0.35 | ) | $ | — | |||||||||||
Non-GAAP Net Income (Loss) Per Diluted Share | $ | 0.08 | $ | — | $ | (0.19 | ) | $ | 0.17 | ||||||||||||
Weighted average number of diluted shares | 22,948 | 21,794 | 22,904 | 22,920 | |||||||||||||||||
1Results for all periods presented include changes in fair value of contingent consideration obligations associated with the Solar Implant Technology (SIT) acquisition in 2010. |
2Results for the year ended |
3Results for the fourth quarter and year ended |
4The amount represents the estimated income tax effect of the non-GAAP adjustments. The Company calculated the tax effect of non-GAAP adjustments by applying an applicable estimated jurisdictional tax rate to each specific non-GAAP item. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190130005211/en/
Chief Financial Officer
(408) 986-9888
Investor Relations
(530) 265-9899
Source: